



PATENT
Docket No. 265.00440101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Boldogh et al.) Group Art Unit: 1653
Serial No.: 10/691,157)
Confirmation No.: 6536)
Filed: October 22, 2003)
For: USE OF COLOSTRININ, CONSTITUENT PEPTIDES THEREOF, AND
ANALOGS THEREOF AS MODULATORS OF INTRACELLULAR
SIGNALING MOLECULES

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with C.F.R. §§ 1.97 *et. seq.*, the materials enclosed herewith are brought to the attention of the Examiner as possibly being of interest in connection with the above-identified patent application. Per M.P.E.P. § 609, the information cited in the present Information Disclosure Statement shall not be construed to be an admission that the information is, or is considered to be, material to patentability. Consideration of each of the documents listed on the attached 1449 form(s) is respectfully requested. Pursuant to the provisions of M.P.E.P. §609, Applicants further request that a copy of the 1449 form(s), marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

Since this Supplemental Information Disclosure Statement is submitted after the receipt of an Office Action in the above-identified patent application, please charge Deposit Account No. 13-4985 the fee of \$180 under 37 C.F.R. §§1.97(c) and 1.17(p). Please charge any additional fees or credit any overpayment to Deposit Account No. 13-4895.

Supplemental Information Disclosure Statement

Page 2 of 2

Applicant(s): Boldogh et al.

Serial No.: 10/691,157

Confirmation No.: 6536


Filed: 22 October 2003

For: USE OF COLOSTRININ, CONSTITUENT PEPTIDES THEREOF, AND ANALOGS THEREOF AS
MODULATORS OF INTRACELLULAR SIGNALING MOLECULES

The Examiner is invited to contact Applicants' Representatives at the below-listed telephone number, if they can be of any assistance during prosecution of the present application.

CERTIFICATE UNDER 37 C.F.R. 1.10:

The undersigned hereby certifies that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR §1.10 on the date indicated below and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Name: Sarah W. Grant
"Express Mail" mailing label number:
EV 201892344 US
Date of Deposit: August 29, 2005

Respectfully submitted for

Boldogh et al.

By

Mueeting, Raasch & Gebhardt, P.A.

P.O. Box 581415

Minneapolis, MN 55458-1415

Phone: (612)305-1220

Facsimile: (612)305-1228

Customer Number 26813

August 29, 2005
Date

By: 
Nancy A. Johnson
Reg. No. 47,266
Direct Dial (612)305-4723



INFORMATION DISCLOSURE STATEMENT	Atty. Docket No.: 265.00440101	Serial No.: 10/691,157
	Applicant(s): Boldogh et al.	Confirmation No.: 6536
	Application Filing Date: 22 October 2003	Group: 1653
	Information Disclosure Statement mailed: August <u>29</u> , 2005	

U.S. PATENT DOCUMENTS

Examiner Initial	Copy Enclosed	Document Number	date	Name	Class	Subclass	Filing Date If Appropriate
		6,852,685	02/08/05	Boldogh et al.			
		6,852,700	02/08/05	Janusz et al.			
		6,903,068	06/07/05	Stanton et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initial	Copy Enclosed	Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	X	WO 04/37851	05/06/04	PCT				
	X	WO 95/00155	01/05/95	PCT				

OTHER DOCUMENTS (Including Authors, Title, Date, Pertinent Papers, etc.)

Examiner Initial	Copy Enclosed	Document Description
	X	Boldogh et al., "Modulation of 4HNE-Mediated Signaling by Colostrinin: Clinical Implications in Ad," <i>18th International Conference of Alzheimer's Diseases International III Conferencia Nacional Alzheimer</i> , Barcelona Spain, October 23-26, 2002, Abstract.
	X	Boldogh et al., "Modulation of 4HNE-Mediated Signaling by Proline-Rich Peptides from Ovine Colostrum," <i>18th International Conference of Alzheimer's Diseases International III Conferencia Nacional Alzheimer</i> , Barcelona Spain 2002, Poster.
	X	Boldogh et al., "Antioxidant and cell-differentiating activity of colostrinin and its component peptides (CCP) in cell culture," <i>Psychogeriatr Ann</i> , 2001;4: 57-65.
	X	Kruzel and Georgiades, "Colostrinin@: A New Frontier for an Old Structure," <i>Rocznik Psychogeriatryczny</i> , 2001;4:77-84

EXAMINER	Date Considered
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



INFORMATION DISCLOSURE STATEMENT	Atty. Docket No.: 265.00440101	Serial No.: 10/691,157
	Applicant(s): Boldogh et al.	Confirmation No.: 6536
	Application Filing Date: 22 October 2003	Group: 1653
	Information Disclosure Statement mailed: August 29, 2005	

Examiner Initial	Copy Enclosed	Document Description
	X	Polish Society of Psychiatry Psychogeriatric and Alzheimer's Disease Section, "Treatment of Psychiatric Disorders in Aged Patients," <i>First International Symposium on Colostrinin</i> , ReGen Therapeutics Plc, 1 December 2000, Lodz Poland, Brochure.
	X	Stanton et al., "Induction of proliferation and cytokines by colostrinin and component proline rich peptides in huyma periferal blood leukocytes," <i>Psychogeriatr. Ann</i> , 2001;4:67-75

EXAMINER	Date Considered
<small>*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>	